Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458367 | 1.00 | PDE4B (0.46) | PDE4BNR1H2USP30EPHX1CTSK | |
| SCHEMBL1580422 | 0.88 | CTSK (0.40) | PDE4BUSP30CTSKCA1CA2 | |
| SCHEMBL4984187 | 0.88 | USP30 (0.45) | PDE4BNR1H2USP30EPHX1USP2 | |
| SCHEMBL3824957 | 0.88 | CTSK (0.40) | PDE4BUSP30CTSKCA1CA2 | |
| SCHEMBL3608719 | 0.88 | NR1H2 (0.44) | PDE4BNR1H2USP30EPHX1USP2 | |
| SCHEMBL744174 | 0.88 | CTSK (0.40) | PDE4BUSP30CTSKCA1CA2 | |
| SCHEMBL4984190 | 0.88 | USP30 (0.45) | PDE4BNR1H2USP30EPHX1USP2 | |
| SCHEMBL10060056 | 0.87 | NR1H2 (0.43) | PDE4BNR1H2USP30EPHX1CTSK | |
| SCHEMBL27659323 | 0.87 | HSD11B1 (0.48) | PDE4BUSP30EPHX1CTSKCA1 | |
| SCHEMBL27638306 | 0.87 | HSD11B1 (0.48) | PDE4BUSP30EPHX1CTSKCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3284745-A1 | COMPOSITION OF (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | Sunesis Pharmaceuticals, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9839630-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170226104-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | SUNESIS PHARMACEUTICALS INC (US) | 2017-08-10 | — | — | US | disclosed |
| EP-2315768-B1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2017-08-09 | — | — | EP | disclosed |
| EP-2382214-B1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20170035741-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170035741-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20150157614-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150157614-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8802719-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802719-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140171660-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. | 2014-06-19 | — | — | US | disclosed |
| US-20140171660-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. | 2014-06-19 | — | — | US | disclosed |
| US-8637491-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2014-01-28 | — | — | US | disclosed |
| US-8497282-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497282-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110172191-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2011-07-14 | — | — | US | disclosed |
| US-20100203162-A1 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157614-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | CYP7A1, MT-ND1, DNM1 | PDE4B 1014/4885NR1H2 1541/4885USP30 4818/4885 |
| US-20100203162-A1 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | CYP7A1, MT-ND1, DNM1 | PDE4B 1014/4885NR1H2 1541/4885USP30 4818/4885 |
| US-20110172191-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP2K2, MAP2K1, MAP2K3 | PDE4B 2087/4885NR1H2 3188/4885USP30 2621/4885 |
| US-20170035741-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | CYP7A1, MT-ND1, DNM1 | PDE4B 1014/4885NR1H2 1541/4885USP30 4818/4885 |
| US-20140171660-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | CYP7A1, DNM1, MT-ND1 | PDE4B 973/4885NR1H2 1413/4885USP30 4758/4885 |
| US-20170226104-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | NES, NCDN, NCL | PDE4B 2075/4885NR1H2 3143/4885USP30 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.